Clinico-epigenetic combination including quantitative methylation value of DKK3 augments survival prediction of the patient with cervical cancer

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 1, 2013, Pages 97-106

  Kang, Woong Sun ^a   Cho, Sung Bum ^b   Park, Jun Soo ^c   Lee, Moo Yul ^d   Myung, Soon Chul ^d   Kim, Won Yong ^d   Lee, Sang Hoon ^d   Kim, Dong Ho ^d   Lee, Eun Ju ^d  

^a Seoul Women's Hospital   (South Korea)

^b Korea National Institute of Health   (South Korea)

^c Yonsei University Wonju   (South Korea)

^d Chung Ang University College of Medicine   (South Korea)

Author keywords

DKK3; DNA Methylation; Prognosis; Quantitative evaluation; Uterine cervical cancer

Indexed keywords

PROTEIN DKK3; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; CPG ISLAND; DISEASE FREE SURVIVAL; EPIGENETICS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; UTERINE CERVIX CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CPG ISLANDS; DISEASE-FREE SURVIVAL; DNA METHYLATION; EPIGENOMICS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPUBLIC OF KOREA; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84872329892     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1262-7     Document Type: Article

References (27)

1. Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA (2001) Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 3:683-686. doi: 10.1038/35083081
2. Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, Deasel M, Germonpre P, Rubinson L, Heitmiller RF, Yang SC, Forastiere AA, Baylin SB, Herman JG (2003) Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 9:2912-2919
3. Cannistra SA, Niloff JM (1996) Cancer of the uterine cervix. N Engl J Med 334(16):1030-1038. doi: 10.1056/NEJM199604183341606
4. Chou CY, Wang ST, Kuo HC, Tzeng CC, Yao BL (1994) Serum level of squamous cell carcinoma antigen and tumor size are useful to identify preoperatively patients at high risk of cervical cancer. Cancer 74(9):2497-2501
5. Chung HH, Jang MJ, Jung KW, Won YJ, Shin HR, Kim JW, Lee HP, Members for Gynecologic Oncology Committee of Korean Society of Obstetrics and Gynecology (2006) Cervical cancer incidence and survival in Korea: 1993-2002. Int J Gynecol Cancer 16(5):1833-1838. doi: 10.1111/j.1525-1438.2006.00708.x
6. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354. doi: 10.1056/NEJM200011093431901
7. Fraga MF, Esteller M (2002) DNA methylation: a profile of methods and applications. Biotechniques 33(3):632, 634, 636-649
8. Gerdes B, Ramaswamy A, Ziegler A, Lang SA, Kersting M, Baumann R, Wild A, Moll R, Rothmund M, Bartsch DK (2002) p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb. Ann Surg 235:51-59
9. Graziano F, Arduini F, Ruzzo A, Bearzi I, Humar B, More H, Silva R, Muretto P, Guilford P, Testa E, Mari D, Magnani M, Cascinu S (2004) Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin Cancer Res 10:2784-2789
10. Holtz DO, Dunton C (2002) Traditional management of invasive cervical cancer. Obstet Gynecol Clin North Am 29(4):645-657
11. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3(6):415-428. doi: 10.1602/neurorx.1.2.182
12. Kobayashi K, Ouchida M, Tsuji T, Hanafusa H, Miyazaki M, Namba M, Shimizu N, Shimizu K (2002) Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene 282:151-158
13. Komaki R, Brickner TJ, Hanlon AL, Owen JB, Hanks GE (1995) Long-term results of treatment of cervical carcinoma in the United States in 1973, 1978, and 1983: Patterns of Care Study (PCS). Int J Radiat Oncol Biol Phys 31(4):973-982
14. Lee EJ, Jo M, Rho SB, Park K, Yoo YN, Park J, Chae M, Zhang W, Lee JH (2009) Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin. Int J Cancer 124(2):287-297. doi: 10.1002/ijc.23913
15. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H (2005) Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 65:4218-4227. doi: 10.1158/0008-5472.CAN-04-4407
16. Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, Niehrs C (2001) LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411:321-325. doi: 10.1038/35077108
17. Mayeux R (2004) Biomarkers: potential uses and limitations. NeuroRx 1(2):182-188
18. Mikeska T, Bock C, El-Maarri O, Hübner A, Ehrentraut D, Schramm J, Felsberg J, Kahl P, Büttner R, Pietsch T, Waha A (2007) Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfate restriction analysis. J Mol Diagn 9(3):368-381. doi: 10.2353/jmoldx.2007.060167
19. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74-108
20. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro G, Molina FJ, Calasanz MJ, Prosper F, Heiniger A, Torres A (2004) Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 104(8):2492-2498. doi: 10.1182/blood-2004-03-0954
21. Scully RE, Bonfigiro TA, Kurman RJ, Silverberg SG, Wilkinson EJ (1994) Histological typing of female genital tract tumors, 2nd edn. Springer, Berlin
22. Shin HR, Jung KW, Won YJ, Kong HJ, Yim SH, Sung J, Seo SW, Kim KY, Lee SY, Kong IS, Hwang IK, Lee CW, Woo ZH, Lee TY, Choi JS, Yoo CI, Bae JM, Yoo KY (2007) National cancer incidence for the year 2002 in Korea. Cancer Res Treat 39(4):139-149. doi: 10.4143/crt.2007.39.4.139
23. Sobin LH, Wittekind CH (2002) TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York
24. Toyooka S, Suzuki M, Maruyama R, Toyooka KO, Tsukuda K, Fukuyama Y, Iizasa T, Aoe M, Date H, Fujisawa T, Shimizu N, Gazdar AF (2004) The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer 91:771-774. doi: 10.1038/sj.bjc.6602013
25. Tsuji T, Miyazaki M, Sakaguchi M, Inoue Y, Namba M (2000) A REIC gene shows down-regulation in human immortalized cells and human tumor-derived cell lines. Biochem Biophys Res Commun 268(1):20-24. doi: 10.1006/bbrc.1999.2067
26. Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, Hirata H, Tanaka Y, Kikuno N, Nakagawa M, Igawa M, Dahiya R (2006) Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res 12:2109-2116. doi: 10.1158/1078-0432.CCR-05-2468
27. Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E, Jones PA, Laird PW (2004) Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64:3807-3813. doi: 10.1158/0008-5472.CAN-03-3852